Scientia Clinical trial is seeking participants to join a clinical trial. The clinical trial involves wearing a patch for one week. Participants will need to be available for 10 days and 9 nights followed by 4 short follow-ups.
Multiple sclerosis is a condition that affects over 25,600 Australians. An oral drug fingolimod is approved by the TGA in Australia for the treatment of this condition. To reduce side effect and improve patient compliance, a patch form of fingolimod is being investigated. If you fit the following criteria, you may be able to help.
You may be eligible if you are:
- Caucasian female, generally healthy
- Aged 25 to 50 (inclusive)
- Has a BMI between 18-32kg/m2
- Has a fair skin tone
